Prognosis
FDA Staff Makes No Recommendation on J&J Covid Shot Booster
- Advisory panel will convene Friday to discuss authorization
- J&J vaccine continues to protect against severe disease, death
This article is for subscribers only.
U.S. regulators didn’t make a recommendation on whether recipients of the Johnson & Johnson Covid-19 vaccine should receive a booster, ahead of a closely watched meeting where scientific experts will weigh whether study data supports giving the additional dose.
On Friday, the Food and Drug Administration’s advisers will convene to guide the agency on J&J’s request for an emergency-use authorization of a second shot. In a 54-page report released Wednesday in preparation, the agency’s staff didn’t make a formal recommendation for the panel.